Patents by Inventor Stefan Seeber

Stefan Seeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE
    Publication number: 20140370019
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: December 18, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 8900581
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: December 2, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Pickl, Carola Ries, Stefan Seeber, Kerstin Krueger
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20140336363
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against IL-18R1 and uses thereof
    Patent number: 8883975
    Abstract: The invention provides anti-IL-18R1 antibodies and methods of using the same.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Michael Brandt, Jens Fischer, Stefan Jenewein, Klaus Kaluza, Eileen Samy, Stefan Seeber
  • CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE
    Publication number: 20140315252
    Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 23, 2014
    Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN IL33R AND USES THEREOF
    Publication number: 20140302015
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE REGION GENE SEGMENTS
    Publication number: 20140302559
    Abstract: In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Simone Hoege, Erhard Kopetzki, Dominique Ostler, Stefan Seeber, Georg Tiefenthaler
  • Antibodies against human IL33R and uses thereof
    Patent number: 8785153
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 8703130
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: April 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20130005949
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 3, 2011
    Publication date: January 3, 2013
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20120329997
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 3, 2011
    Publication date: December 27, 2012
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20120321627
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 20, 2012
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 8268314
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Antibodies against human IL33R and uses thereof
    Publication number: 20120213774
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Antibodies against IL-18R1 and uses thereof
    Publication number: 20120156198
    Abstract: The invention provides anti-IL-18R1 antibodies and methods of using the same.
    Type: Application
    Filed: August 25, 2011
    Publication date: June 21, 2012
    Inventors: Michael Brandt, Jens Fischer, Stefan Jenewein, Klaus Kaluza, Eileen Samy, Stefan Seeber
  • HUMAN Fc GAMMA RECEPTOR III
    Publication number: 20110183354
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 1, 2011
    Publication date: July 28, 2011
    Inventors: ULRICH BRINKMANN, PETER BRUENKER, CLAUDIA FERRARA KOLLER, MARTIN LANZENDOERFER, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, ANNE ZECK
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20110165156
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 7, 2010
    Publication date: July 7, 2011
    Inventors: NIKOLAOS DIMOUDIS, GEORG FERTIG, ALEXANDER FIDLER, KLAUS KALUZA, MARLENE PICKL, CAROLA RIES, STEFAN SEEBER, MARTIN LANZENDOERFER, KERSTIN KRUEGER
  • ANTIBODIES AGAINST IL-13 RECEPTOR ALPHA 1 AND USES THEREOF
    Publication number: 20110086026
    Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
    Type: Application
    Filed: July 26, 2010
    Publication date: April 14, 2011
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • ANTI-OX40L ANTIBODIES
    Publication number: 20110070239
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 24, 2011
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Anti-OX40L antibodies
    Patent number: 7868141
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 11, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt